Long-acting muscarinic antagonist (LAMA) plus long-acting beta-agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable chronic obstructive pulmonary disease-Reference-Cited by-同舟云学术

Long-acting muscarinic antagonist (LAMA) plus long-acting beta-agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable chronic obstructive pulmonary disease

Published:2023-06-05 Issue:6 Volume:2023 Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Fukuda Nobuhiko¹,Horita Nobuyuki¹,Kaneko Ayami¹,Goto Atsushi²,Kaneko Takeshi¹,Ota Erika³,Kew Kayleigh M⁴

Affiliation:

1. Department of Pulmonology; Yokohama City University Graduate School of Medicine; Yokohama Japan

2. Metabolic Epidemiology Section, Division of Epidemiology; Center for Public Health Sciences, National Cancer Center; Tokyo Japan

3. Global Health Nursing, Graduate School of Nursing Science; St. Luke's International University; Tokyo Japan

4. Cochrane Central Executive; London UK

Publisher

Wiley

Subject

Pharmacology (medical)

Reference100 articles.

1. The lung function profile of once-daily tiotropium and olodaterol via Respimat is superior to that of twice-daily salmeterol and fluticasone propionate via Accuhaler (ENERGITO study);Beeh;International Journal of Chronic Obstructive Pulmonary Disease,2016

2. Tiotropium + olodaterol provides significant lung-function benefits compared to fluticasone + salmeterol regardless of prior bronchodilator use;Derom;European Respiratory Journal,2016

3. Efficacy and safety of umeclidinium/vilanterol (UMEC/VI) once daily (OD) vs fluticasone/salmeterol combination (FSC) twice daily (BD) in patients with moderate-to-severe COPD and infrequent COPD exacerbations;Donohue;Chest,2014

4. Improvements in lung function with umeclidinium/vilanterol versus fluticasone propionate/salmeterol in patients with moderate-to-severe COPD and infrequent exacerbations;Donohue;Respiratory Medicine,2015

5. Efficacy and safety of umeclidinium/vilanterol (UMEC/VI) once daily (OD) vs fluticasone/salmeterol combination (FSC) twice daily (BD) in patients with moderate-to-severe COPD and infrequent COPD exacerbations;Donohue;Chest,2014

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Revisión narrativa de la terapia inhalatoria en la EPOC;Medicina de Familia. SEMERGEN;2024-10

2. Recent Advances in Chronic Obstructive Pulmonary Disease;COPD - Pathology, Diagnosis, Treatment, and Future Directions;2024-06-05

3. Inhaled corticosteroid treatment and pneumonia in patients with chronic obstructive pulmonary disease – nationwide development from 1998 to 2018;European Clinical Respiratory Journal;2024-05-29

4. How does long-acting muscarinic antagonist (LAMA) plus long-acting beta-agonist (LABA) compare with LABA plus inhaled corticosteroid (ICS) for people with stable chronic obstructive pulmonary disease (COPD)?;Cochrane Clinical Answers;2023-08-08